Different β -Blockers in STEMI and Primary PCI
Not Applicable
Not yet recruiting
- Conditions
- Primary PCI
- Interventions
- Drug: β -Blockers
- Registration Number
- NCT04221919
- Lead Sponsor
- Qilu Hospital of Shandong University
- Brief Summary
Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily
- Detailed Description
The investigators will investigate the efficacy and safety of different β -blockers, as well as heart rate variability, in STEMI patients undergoing primary PCI.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
- Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes;
- Age ≥18 years;
- Informed consent from patient or next of kin.
Exclusion Criteria
- Nonischaemic Cardiomyopathy;
- Cardiac surgery planed in the 6 months;
- Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation);
- Renal or hepatic failure;
- Malignancy, HIV, or central nervous system disorder;
- Cardiopulmonary resuscitation >15 min and compromised level of consciousness;
- Cardiogenic shock;
- Current participation in any research study involving investigational drugs or devices;
- No written consensus;
- Previous myocardial infarction.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Carvedilol β -Blockers - Bisoprolol β -Blockers - Metoprolol tartrate β -Blockers - Metoprolol succinate β -Blockers -
- Primary Outcome Measures
Name Time Method Change in LVEDV from baseline 1 to 5 years The primary outcome of this study will be the change from baseline in left ventricular end diastolic volume (LVEDV) post-PCI.
Major adverse cardiovascular events (MACE) 1 to 5 years
- Secondary Outcome Measures
Name Time Method